Randomised Controlled Trial Investigation of a Non-stimulant in Attention Deficit Hyperactivity Disorder

非兴奋剂治疗注意力缺陷多动障碍的随机对照试验研究

• 批准号: nhmrc : 457424
• 负责人: A/Pr Michael Kohn
• 金额: $ 39.27万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-controlled-trial-hyperactivity-disorder/100745
• 关键词: Randomised; Controlled; Trial; Investigation; Non

Atomoxetine (ATMX) is a viable non-stimulant alternative to treat Attention Deficit Hyperactivity Disorder (ADHD), however, clinicians require more objective information on its effectiveness. This is the first study to examine the effectiveness of ATMX using objective cognitive and emotion markers in ADHD. The outcomes from this project will be a significant step towards a 'personalised medicine' approach to ADHD, providing clinicians with increased options in the treatment of ADHD. ADHD is considered the most common neurodevelopmental or child psychiatric disorder. ADHD affects approximately 10% of children and adolescents, in other words, 'at least one in every classroom'. ADHD has a significant burden, including treatment costs, family stress, loss of productivity, increased risk of drug abuse and accidents. It is increasingly clear that new medications need to be evaluated to make ADHD treatment more effective and efficient. The vast majority of medicated ADHD individuals are treated with stimulants, which are controlled substances. A large number do not respond to stimulant treatment, and in others the potential for abuse remains. Some ADHD report negative feelings about taking stimulants and there is growing concern about increasing prescription rates. ATMX is a recently approved non-stimulant (therefore, non-controlled) to treat ADHD, with evidence of clinical effectiveness. Yet, the impact of ATMX on objective measures of a range of cognitive and emotional function has not been studied. Several lines of evidence indicate it is effective for these functions. ATMX has been shown to alleviate inhibitory capacity, while stimulants have not. Of the 30% of ADHD who do not respond to stimulants, the least responsive are those categorized as 'internalizing' types who show allied anxiety. Common disturbances may underlie abnormal inhibitory capacity and impaired emotional recognition in ADHD that is best treated with ATMX rather than stimulants.

阿托西汀 (ATMX) 是一种治疗注意力缺陷多动障碍 (ADHD) 的可行的非兴奋剂替代品，但是，临床医生需要有关其有效性的更客观信息。这是第一项使用客观认知和情绪标记来检验 ATMX 在 ADHD 中的有效性的研究。该项目的成果将是朝着 ADHD 的“个性化医疗”方法迈出的重要一步，为临床医生提供更多的 ADHD 治疗选择。 ADHD 被认为是最常见的神经发育或儿童精神疾病。大约 10% 的儿童和青少年患有多动症，换句话说，“每个教室至少有一名儿童和青少年”。多动症带来了巨大的负担，包括治疗费用、家庭压力、生产力损失、药物滥用和事故风险增加。越来越明显的是，需要对新药物进行评估，以使多动症治疗更加有效和高效。绝大多数接受药物治疗的多动症患者都接受兴奋剂治疗，这些药物是受控物质。许多人对兴奋剂治疗没有反应，而在其他人中，滥用的可能性仍然存在。一些注意力缺陷多动症患者表示对服用兴奋剂有负面感觉，并且人们越来越担心处方率的增加。 ATMX 是最近批准的一种非兴奋剂（因此非对照）用于治疗 ADHD，并有临床有效性证据。然而，ATMX 对一系列认知和情感功能的客观测量的影响尚未得到研究。多项证据表明它对这些功能有效。 ATMX 已被证明可以减轻抑制能力，而兴奋剂则不然。在 30% 对兴奋剂没有反应的多动症患者中，反应最差的是那些表现出相关焦虑的“内化”类型的人。常见的紊乱可能是 ADHD 抑制能力异常和情绪识别受损的基础，最好用 ATMX 治疗，而不是兴奋剂。